“As a nurse with clinical training, I am new to research, and it has been an exciting transition but also one that has involved developing several new skills. Respiratory research is thriving, and the team is currently recruiting for a diverse range of studies.
“One of these studies, TILIA (D9185C00001), is a Phase III trial researching the efficacy and safety of Tozorakimab in patients requiring hospitalization and supplemental oxygen due to a viral lung infection. Tozorakimab is an antibody thought to reduce levels of Interleukin-33, which is produced following a viral infection and causes inflammation. The study aims to investigate if Tozorakimab decreases the patient’s requirement for invasive mechanical ventilation when administered within 36 hours of admission.
“TILIA is one of the first studies the team educated me on and one of the first studies I approached potential participants for. Assisting with this trial has been an incredibly rewarding process. One elderly participant who was normally fit and well was sadly admitted to the hospital due to Influenza A. They were unwell, requiring high-flow nasal oxygen, but consented to partake in the TILIA study. It has been a fantastic experience to follow this participant up, to see them weaned from requiring oxygen, then to be discharged home, and now return to their passion for hiking.
“As TILIA is a blinded study, we are still determining Tozorakimab’s impact on viral respiratory infections. However, it is a privilege to witness positive patient progression. I am also excited to see the results of the TILIA study in the future, and I am proud to know I have played a small role in gathering data that impacts future care.
“With Dr Dipansu Ghosh leading the study, we have recruited very well, surpassing our initial target of 3. To date, we have recruited 8 patients and have been asked to share our experience with other sites”.